Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of GDC-0919 (navoximod) in recurrent advanced solid tumors
NCT02048709Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navoximod in solid tumor, sponsored by Genentech. Primary endpoints: Percentage of patients with dose-limiting toxicities at 28 days, Number of dose-limiting toxicities at 28 days and 1 more. Started Apr 2014; status: completed.
02
Drugs
navoximod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02048709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048709.